Radiopharmaceutical/Radioligand Therapy Platform

Radiomer Therapeutics is focused on developing a novel radiopharmaceutical and radioligand therapy platform that utilizes Raptamersᵀᴹ, which are innovative peptide-oligonucleotide hybrids. These Raptamers serve as targeting moieties or vectors, enabling precise delivery of therapeutic agents to specific cells or tissues. This technology aims to enhance the efficacy of treatments while minimizing off-target effects, making it a promising approach in the field of targeted therapy.

The company's pipeline includes various products that leverage this advanced technology to address unmet medical needs, particularly in oncology. By combining the specificity of peptide targeting with the versatility of oligonucleotides, Radiomer Therapeutics is positioned to develop therapies that can effectively target and treat cancerous cells, potentially leading to improved patient outcomes and reduced side effects compared to traditional treatment modalities.

Denmark

Radiomer Therapeutics, Inc. is a Fannin-founded company that is developing targeted radiopharmaceuticals for cancer treatment.

Radiomer Therapeutics

Company Details